Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News

TOP industry news from Business Wire

Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)Open in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #ADA--Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)


Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific SessionsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals today presented additional data from an exploratory Phase IIa study of praliciguat during an oral session at ADA 2018.


Pierre Fabre & Array BioPharma annoncent à l’ESMO GI un taux de survie globale observée à un an de 62 % (phase 3 BEACON) avec la triple association encorafenib, binimetinib et cétuximab chez les patients atteints d’un CRC avec mutation BRAFOpen in a New Window

CASTRES--(BUSINESS WIRE)--Non destiné aux organes de presse britanniques et américains Pierre Fabre et son partenaire, Array BioPharma Inc., ont présenté aujourd’hui de nouveaux résultats de tolérance et d’efficacité, y compris sur la Survie Globale (SG) issus de la « safety lead-in phase » (phase de test de la tolérance) de l’essai de phase 3 BEACON CRC portant sur l’association d’encorafenib, un inhibiteur de BRAF, de binimetinib, un inhibiteur de MEK, et de cétuximab, un anticorps anti-EGFR,


Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI CongressOpen in a New Window

CASTRES, France--(BUSINESS WIRE)--Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analys


Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and TaihoOpen in a New Window

PARIS--(BUSINESS WIRE)--Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients


Association Management Software Powered by YourMembership  ::  Legal